This analyst loves Equillium

Roth Capital Partners analyst Adam Walsh initiated coverage of Equillium (Equillium Stock Quote, Chart, News, Analysts, Financials NASDAQ:EQ) with a “Buy” rating and US$12.00 price target, citing the potential of the company’s lead program targeting ulcerative colitis.

Equillium is a biotechnology company developing therapies for severe autoimmune and inflammatory diseases. Walsh said the firm’s lead candidate, EQ504, is a colon-targeted oral therapy entering Phase 1 trials for Ulcerative Colitis, a market he estimates at more than US$12-billion.

Walsh said current remission rates remain below 30% across more than 15 approved therapies, most of which rely on immunosuppression. EQ504 instead targets the aryl hydrocarbon receptor (AhR), which can both reduce inflammation and repair gut tissue.

The mechanism has been validated in clinical studies using indigo naturalis, a botanical compound that activates AhR. Walsh said controlled trials of indigo naturalis demonstrated placebo-adjusted remission rates of up to 50%, roughly double the typical ceiling of approved therapies, although the compound itself is not suitable as a drug due to safety and formulation issues.

Walsh said EQ504 was designed to replicate the AhR mechanism while improving potency and delivery. The drug is about 200 times more potent at the AhR receptor than indigo naturalis and is formulated to achieve greater than 25-times tissue-to-systemic concentration through colon-targeted delivery.

Phase 1 trials, expected to begin in mid-2026 in Australia, will measure AhR activation directly in colon tissue through biomarkers including CYP1A1, IL-10 and IL-22, which were predictive of remission in prior indigo naturalis studies. Topline data are expected late 2026 or early 2027.

Walsh said three potential outcomes from the study could drive a revaluation of the stock: confirmation of safety through colon-targeted delivery, biomarker activation comparable to indigo naturalis, and early clinical signals if ulcerative colitis patients are enrolled in the second part of the trial.

He added that recent clinical success from Abivax SA and its drug obefazimod may further validate the AhR pathway, though the connection has not yet been widely recognized by investors.

Equillium had US$33-million in cash as of September 2025 and an additional US$20-million in pre-funded warrants expected to be exercised when the Phase 1 trial begins, which Walsh said should fund operations through the end of 2027.

Walsh estimates potential peak sales for EQ504 of US$3.15-billion and models a possible pharmaceutical acquisition following Phase 2 data, citing transactions such as Morphic Holding’s US$3.2-billion acquisition by Eli Lilly and Company in 2024 after Phase 2 ulcerative colitis results.

-30-